Serum soluble nucleosome and the broad family of antinucleosome antibodies are associated with organ and tissue damage in systemic lupus erythematosus in a Chinese population

被引：7

作者：

Wu, O. ^{[1
]}

Liu, H. H. ^{[1
]}

Li, W. X. ^{[1
]}

Zhang, N. ^{[1
]}

Wang, Q. ^{[1
]}

Li, X. P. ^{[1
,2
]}

Dong, M. X. ^{[1
,3
]}

Zhang, X. J. ^{[1
,4
]}

Ye, D. Q. ^{[1
]}

机构：

[1] Anhui Med Univ, Dept Epidemiol & Biostat, Anhui, Peoples R China

[2] Anhui Prov Hosp, Dept Rheumatol, Anhui, Peoples R China

[3] Natl Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA

[4] Anhui Med Univ, Dept Dermatol, Affiliated Hosp 1, Anhui, Peoples R China

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2008年 / 33卷 / 02期

关键词：

D O I：

10.1111/j.1365-2230.2007.02669.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Nucleosomes and the broad family of antinucleosome antibodies (ANAs; anti-double-stranded DNA, antihistone and antinucleosome antibodies) may contribute to the pathogenesis of systemic lupus erythematosus (SLE). We collected clinical information on 90 patients with SLE and 73 healthy volunteers and measured serum levels of the ANA family using a double-sandwich ELISA. The results showed that the levels of serum nucleosomes of patients with SLE was significantly lower and the levels of ANA were significantly higher than healthy controls. Negative correlations between serum nucleosomes and ANA, and positive correlations between individual ANAs were found. Patients with SLE with positive ANA had a significantly higher frequency of renal disorders than those with negative ANA. Determination of serum nucleosomes and ANAs contributes to SLE monitoring.

引用

页码：160 / 163

页数：4

共 10 条

[1] Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus - Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity [J].

Amoura, Z ;

Piette, JC ;

Chabre, H ;

Cacoub, P ;

Papo, T ;

Wechsler, B ;

Bach, JF ;

Koutouzov, S .

ARTHRITIS AND RHEUMATISM, 1997, 40 (12) :2217-2225

[2] Disease activity and antinucleosome antibodies in systemic 1upus erythematosus [J].

Benucci, M ;

Gobbi, FL ;

Del Rosso, A ;

Cesaretti, S ;

Niccoli, L ;

Cantini, F .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2003, 32 (01) :42-45

[3] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].

BOMBARDIER, C ;

GLADMAN, DD ;

UROWITZ, MB ;

CARON, D ;

CHANG, CH .

ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640

[4]

Burlingame Rufus W., 2002, Autoimmunity Reviews, V1, P321, DOI 10.1016/S1568-9972(02)00083-6

[5] Nucleosome autoantibodies [J].

Decker, P .

CLINICA CHIMICA ACTA, 2006, 366 (1-2) :48-60

[6] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].

Hochberg, MC .

ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725

[7]

Min DJ, 2002, CLIN EXP RHEUMATOL, V20, P13

[8] An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study [J].

Ravirajan, CT ;

Rowse, L ;

MacGowan, JR ;

Isenberg, DA .

RHEUMATOLOGY, 2001, 40 (12) :1405-1412

[9] Anti-DNA antibody subpopulations and lupus nephritis [J].

Rekvig, OP ;

Kalaaji, M ;

Nossent, H .

AUTOIMMUNITY REVIEWS, 2004, 3 (02) :91-96

[10]

Williams RC, 2001, J RHEUMATOL, V28, P81

← 1 →